

DISCLOSURE OF RELEVANT RELATIONSHIPS & CONFIDENTIALITY STATEMENTS
For NIA-AA Guidelines Workgroup

Confidential

DISCLOSURE OF RELEVANT RELATIONSHIPS

For each of the categories below, (1) please disclose relationships that cover the last 12 months and for anticipated activities in the coming 12 months as of approximately April 2016. If you have none, please write "none." Relationships apply to you and to spouse or dependent children. (2) For each relationship, please indicate whether it is a "**Significant (\geq \$1,000) Financial Interest**" Financial interests include but are not limited to salary, consulting and / or speaker fees, honoraria, research support, equity interests (e.g., stocks, stock options, or other ownership interests), and intellectual property rights (e.g., patents, copyrights and royalties from such rights).

1. Research funding (federal, foundation and corporate) relevant to the topic of Alzheimer's disease. The Research Council, Sweden (Significant Financial support), The Torsten Söderberg foundation, Sweden (Significant Financial support), The Swedish Brain Foundation (Significant Financial support), The Swedish Alzheimer Foundation (Significant Financial support), Roche Diagnostics, Switzerland (Significant Financial support), Fujirebio Europe, Belgium (Significant Financial support).

2. Consulting to a for-profit company (paid and unpaid) relevant to the topic of Alzheimer's disease. IBL International, Roche Diagnostics, Fujirebio Europe, Alzheon, Novartis.


3. Ownership of property relevant to the topic of Alzheimer's disease (patents filed or approved, licenses and other property shares) -- for each, please indicate whether you do or do not accept royalties. Co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture based company at University of Gothenburg (no royalties).

4. Equity in companies whose work is relevant to the topic of Alzheimer's disease
None

5. Employment in companies whose work is relevant to the topic of Alzheimer's disease
None

6. Relevant scientific work to the NIA-AA Workgroup discussions. Professor, Head of Laboratory, and Academic Chair in Clinical Neurochemistry, University of Gothenburg, and Sahlgrenska University Hospital. Work on clinical symptoms, clinical heterogeneity, diagnosis, pathogenesis, fluid and imaging markers, and clinical trials in Alzheimer's disease.

I will immediately notify NIA-AA Workgroup leads if a change occurs in any of the above during the tenure of my responsibilities,


Name


Signature


Date